Themis Medicare

Themis Medicare Limited, headquartered in Mumbai, India, is an Indian pharmaceuticals company. It is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and drug formulations. It also supplies its products to a number of other Indian pharmaceutical companies.
Themis was co-founded on November 28, 1952, by three pharmacy graduates Shantibhai, Kantibhai and KP Menon as Therapeutic Pharmaceuticals. Over the years, it was known by names such as Laboratories Orgasyn, Chemosyn Laboratories, and Themis Chemicals (a joint venture with the Hungarian pharmaceutical company Gedeon Richter).
Themis was incorporated in the year 1969, controlled by kins of Shantibhai. As of 2020, its top management includes Dinesh S Patel, Jayshree D Patel, Vijay Agarwal, Rajneesh Anand, Lajos Kovacs, Humayun Dhanrajgir, Hoshang Sinor, Hariharan Subramaniam, Sachind D Patel, Gabor Gulacsi, Reena S Patel. Themis is listed on the Bombay Stock Exchange and the National Stock Exchange.
Themis focuses on therapeutic areas, including anti-tuberculosis, anti-malarial, cardiology, pain management, anti-infectives, haematinics, health and nutrition. Its APIs include Simvastatin, Ethambutol, Artemether, Artesunate, Arteether and Di Methyl Isosorbide. Themis's formulations include original products, new drug delivery systems (NDDS), dietary supplements and others. Its original products include Emal injection, Sepgard Gel, Sepgard Mouth Gargle and Sepgard Solution. Other NDDS include Injection Diclofenac Sodium, Gel Diclofenac Diethylamine, Emal Prefilled Injection, Etojet injection and Injection Aceclofenac. Themis also offers a range of dietary supplements.

Main Menu

See Also

Main Menu